Senseonics Brings Real-World Data to Super-Competitive CGM Market

Conclusion – The Eversense real-world data showed excellent glycemic results, sensor accuracy, and safety. This data demonstrates that the Eversense CGM System is a valuable tool for diabetes management. “This real-world data reflects how the Eversense CGM functions for people who choose this innovative, implantable system to manage their diabetes,” Francine R. Kaufman, MD, Endocrinologist and Chief Medical Officer at Senseonics, said in a release. “The data shows that glucose control, as measured by time in range, is achievable and that there is minimal hypoglycemia. The high wear time and safety record demonstrate that patients are able to rely on the Eversense System in their day-to-day setting. We’re looking forward to sharing these results with the payer community as we seek further coverage for Eversense as a clinically-proven choice in a patient’s CGM therapy.” Senseonics gained FDA approval for a 90-day version of Eversense in 2018. The company is looking to get the regulatory agency to sign off on a 180-version of the CGM and began a pivotal trial for the indication in January.   Getting a Handle on the CGM Landscape   Jason Mills, an analyst with Canaccord Genuity, said that CGM’s are becoming increasingly popular. Mills issued out a research note about the space shortly after the American Diabetes As...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news